Qualit-E-SpeakPharma-Insert
X

Find drug development pipeline and deal Updates information

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Gene Therapy-AAV8

            Therapeutic Area: Endocrinology

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Ultragenyx

            Deal Size: Undisclosed Upfront Cash: $7.0 million

            Deal Type: Licensing Agreement March 31, 2020

            Details:

            Ultragenyx has been granted an exclusive, worldwide license, with rights to sublicense REGENXBIO's NAV AAV8 and AAV9 Vectors for the development and commercialization of gene therapy treatments.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Endocrinology

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: JDRF T1D

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Financing March 25, 2020

            Details:

            The investment from the JDRF T1D Fund wil help company to utilize its core platforms to discover new antigens and T cell receptors in hopes of advancing the development of treatments for T1D.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Gut microbiome based therapeutics

            Therapeutic Area: Endocrinology

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: DuPont

            Deal Size: $15.1 million Upfront Cash: Undisclosed

            Deal Type: Collaboration February 19, 2020

            Details:

            In collaboration, proprietary MRM Health technology platform and some selected DuPont strains will be combined to develop novel therapeutics based on live bacterial strain combinations.